Overview
- Editors:
-
-
Benny K. C. Lo
-
MRC Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK
Access this book
Other ways to access
Table of contents (32 protocols)
-
Antibody Expression And Optimization
-
- Eva Stoger, Stefan Schillberg, Richard M. Twyman, Rainer Fischer, Paul Christou
Pages 301-318
-
- Kevin Brady, Benny K. C. Lo
Pages 319-326
-
-
-
- Syed V. S. Kashmiri, Roberto De Pascalis, Noreen R. Gonzales
Pages 361-376
-
Antibody Characterization and Novel Applications
-
Front Matter
Pages 377-377
-
- Andrea Murray, C. Rosamund L. Graves, Kevin Brady, Benny K. C. Lo
Pages 379-388
-
- Robert Karlsson, Anita Larsson
Pages 389-415
-
- Robert C. Blake II, Diane A. Blake
Pages 417-430
-
- Sotiris Missailidis, Kevin Brady
Pages 431-441
-
-
- Alexandra Huhalov, Daniel I. R. Spencer, Kerry A. Chester
Pages 465-480
-
- Ilse Novak-Hofer, Robert Waibel, Kurt Zimmermann, Jürgen Grünberg, Kerry A. Chester, Andrea Murray et al.
Pages 481-494
-
- Paloma de Prada, Donald W. Landry
Pages 495-501
-
- Ira Pastan, Richard Beers, Tapan K. Bera
Pages 503-518
-
- Andrew R. M. Bradbury, Nileena Velappan, Vittorio Verzillo, Milan Ovecka, Roberto Marzari, Daniele Sblattero et al.
Pages 519-546
-
-
Back Matter
Pages 557-561
About this book
The exquisite binding specificity of antibodies has made them valuable tools from the laboratory to the clinic. Since the description of the murine hybridoma technology by Köhler and Milstein in 1975, a phenomenal number of mo- clonal antibodies have been generated against a diverse array of targets. Some of these have become indispensable reagents in biomedical research, while others were developed for novel therapeutic applications. The attractiveness of an- bodies in this regard is obvious—high target specificity, adaptability to a wide range of disease states, and the potential ability to direct the host’s immune s- tem for a therapeutic response. The initial excitement in finding Paul Ehrlich’s “magic bullet,” however, was met with widespread disappointment when it was demonstrated that murine antibodies frequently elicit the human anti-murine an- body (HAMA) response, thus rendering them ineffective and potentially unsafe in humans. Despite this setback, advances in recombinant DNA techniques over the last 15–20 years have empowered the engineering of recombinant antibodies with desired characteristics, including properties to avoid HAMA. The ability to p- duce bulk quantities of recombinant proteins from bacterial fermentation also fueled the design of numerous creative antibody constructs. To date, the United States Food and Drug Administration has approved more than 10 recombinant antibodies for human use, and hundreds more are in the development pipeline. The recent explosion in genomic and proteomic information appears ready to deliver many more disease targets amenable to antibody-based therapy.
Reviews
"...as the book provides as comprehensive collection of clear, detailed methods it is very likely to prove its worth as a laboratory reference." - Immunology News
"...a valuable addition to in-lab books" - Microbiology Today
Editors and Affiliations
-
MRC Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK
Benny K. C. Lo